

# STEEN SOLUTION™



## For reliable objective assessment of donor lungs

Ex vivo assessment with STEEN Solution™ can expand your lung donor pool. About four of every five lungs offered for transplantation are currently rejected by present selection criteria.<sup>1,2</sup>

However, rejected lungs from marginal and extended donors have been successfully used for transplantation for almost two decades and the concept has now become routine practice at some centers.<sup>3,4,5, 16, 17, 18</sup>

The ex vivo assessment of marginal lung function, including gaseous exchange at 37°C, was developed by Steen et al<sup>6,7,8,9,10</sup> and has since been adopted and modified by other centres.<sup>12,13</sup> The method is now clinically established in many major lung transplant centers worldwide.<sup>16, 17, 19, 20, 21, 22</sup>

During EVLP, the perfusion circuit of the lung mimics *in vivo* conditions; the ventilated lung is perfused with deoxygenated STEEN Solution™ with or without red blood cells and the critical parameters of gaseous exchange, pulmonary vascular resistance, compliance and other key variables under normothermic conditions, are monitored.

Clinical evidence has verified that at least six hours of EVLP is safe with an acellular perfusate and that at least two hours is safe with a cellular perfusate. In the USA, the FDA has granted approval for up to four hours of EVLP with an acellular perfusate.<sup>18, 19, 20, 21, 22</sup>

The STEEN Solution™ perfusate used for EVLP permits:

- Refined functional ex vivo evaluation of accept/reject criteria
- Oncotic pressure preventing edema formation
- Increased usage of donated lungs

STEEN Solution™ is intended for assessment of isolated lungs after removal from the donor body for eventual transplantation into a recipient.

Humanitarian Device. Authorized by Federal law in the USA for use in flushing and temporary continuous normothermic machine perfusion of initially unacceptable excised donor lungs during which time the ex vivo function of the lungs can be reassessed for transplantation. The effectiveness of this device for this use has not been demonstrated.

**XVIVO**  
PERFUSION

## Maintains stability of isolated lungs ex vivo

STEEN Solution™ is a buffered extracellular solution that includes human serum albumin to provide an optimal oncotic pressure and Dextran 40 to coat and protect the endothelium from excessive leucocyte interaction. STEEN Solution™ is designed to facilitate prolonged evaluation and promote stability of isolated lungs ex vivo.

STEEN Solution™ offers flexibility in the choice of EVLP methodology. Safe use of STEEN Solution™ in the Scandinavian and the Toronto protocols is clinically documented.

### STEEN Solution™ contains:

- Human Serum Albumin – provides normal oncotic pressure preventing edema formation
- Dextran 40 – a mild scavenger which coats and protects endothelium from subsequent excessive leucocyte interaction<sup>14, 15</sup>
- Extra-cellular electrolyte composition

### Clinically evaluated EVLP protocols:

#### SCANDINAVIAN PROTOCOL



Red blood cells  
Perfusion flow: 100% CO  
Open left atrium  
CE marked

#### TORONTO PROTOCOL

Acellular  
Perfusion flow: 40% CO  
Closed left atrium  
FDA approved under an HDE  
CE marked

### Supply information:

Reference: 19004	Packaging: 500 ml bottle
---------------------	-----------------------------



Plasma proteins (HSA) and colloid polymers (dextran 40) bind and retain water within capillaries. The coating of the endothelium with dextran 40 prevents excessive leucocyte interaction.

### References

1. Ware LB et al. Lancet 2002; 360:619-20
2. Pierre AF et al. J Thorac Cardiovasc Surg. 2002; 123:3421-8
3. Kron I et al. Ann Surg. 1993; 217:518-24
4. Sundaresan S et al. J Thorac Cardiovasc Surg. 1995; 109:1075-80
5. Shumway S et al. Ann Thorac Surg. 1994; 57:92-5
6. Steen S et al. Lancet 2001; 357:825-829
7. Steen S et al. Ann Thorac Surg. 2003; 76:244-52
8. Cypel M, et al. J Heart Lung Transplant. 2008; 27(12):1319-1325
9. Cypel M, Rubacha M, Yeung J, et al. Am J Transplantation 2009; 9:1-8
10. Steen S, Ingemansson R, Eriksson L, et al. Ann Thorac Surg 2007; 83:2191
11. Ingemansson, R et al. Ann Thorac Surg 2009; 87(1):255-260
12. Neyrinck A et al. J Heart Lung Transplant 2004; 23:173 (abstr)
13. Wierup P et al. Ann Thorac Surg. 2006; 81:460-6
14. Menger MD et al. Transplant Proceed. 1995; 27:5:2863-65
15. Hoffman H et al. Z. Hertz-Thorax-Gefässschir 1997; 11:1:108-14
16. Zych B et al. British J of Transplantation, 2010; 4 (3), 10-16
17. Cypel M, et al. J Thorac Cardiovasc Surg. 2012 Nov; 144(5):1200-6
18. Koike T et al. J Heart Lung Transplant. 2011 Dec; 30 (12):1312-9
19. Munshi L, et al. Lancet Respir Med. 2013 Jun; 1(4):318-28
20. Machuca T N, et al. Surg Clin North Am. 2013 Dec; 93(6):1373-94
21. Sanchez P G, et al. J Heart Lung Transpl. 2012, 31: 339-348.
22. Aigner C, et al. Am. J Transplant. 2012; 12, 1839-1847